AR013201A1 - Proteina interleuquina-6 receptor interleuquina-6 quimerica soluble, analogos de la misma, una secuencia de adn, un vector de adn, celulas de mamifero transformadas incapaz de generar un animal, un metodo para producir una proteina quimerica, la utilizacion de dicha proteina para la preparacion de u - Google Patents

Proteina interleuquina-6 receptor interleuquina-6 quimerica soluble, analogos de la misma, una secuencia de adn, un vector de adn, celulas de mamifero transformadas incapaz de generar un animal, un metodo para producir una proteina quimerica, la utilizacion de dicha proteina para la preparacion de u

Info

Publication number
AR013201A1
AR013201A1 ARP980103377A ARP980103377A AR013201A1 AR 013201 A1 AR013201 A1 AR 013201A1 AR P980103377 A ARP980103377 A AR P980103377A AR P980103377 A ARP980103377 A AR P980103377A AR 013201 A1 AR013201 A1 AR 013201A1
Authority
AR
Argentina
Prior art keywords
interleukine
protein
chemical
util
incapable
Prior art date
Application number
ARP980103377A
Other languages
English (en)
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26323470&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR013201(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from IL12128497A external-priority patent/IL121284A0/xx
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Publication of AR013201A1 publication Critical patent/AR013201A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5412—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/71—Fusion polypeptide containing domain for protein-protein interaction containing domain for transcriptional activaation, e.g. VP16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/95—Fusion polypeptide containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se proveen proteínas quiméricas construidas mediante la fusion de las formas que se presenta naturalmente, del receptor de la IL-6 y de la IL-6solubles, que son utiles para el tratamiento del cáncer y delos trastornos hepáticos, laacentua cion de los transplantes de médula osea, y el tratamientode otras condiciones relacionadas con la IL-6.
ARP980103377A 1997-07-10 1998-07-10 Proteina interleuquina-6 receptor interleuquina-6 quimerica soluble, analogos de la misma, una secuencia de adn, un vector de adn, celulas de mamifero transformadas incapaz de generar un animal, un metodo para producir una proteina quimerica, la utilizacion de dicha proteina para la preparacion de u AR013201A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL12128497A IL121284A0 (en) 1997-07-10 1997-07-10 Chimeric interleukin-6 soluble receptor/ligand protein analogs thereof and uses thereof
IL12281897A IL122818A0 (en) 1997-07-10 1997-12-30 Chimeric interleukin-6 soluble receptor/ligand protein analogs thereof and uses thereof

Publications (1)

Publication Number Publication Date
AR013201A1 true AR013201A1 (es) 2000-12-13

Family

ID=26323470

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980103377A AR013201A1 (es) 1997-07-10 1998-07-10 Proteina interleuquina-6 receptor interleuquina-6 quimerica soluble, analogos de la misma, una secuencia de adn, un vector de adn, celulas de mamifero transformadas incapaz de generar un animal, un metodo para producir una proteina quimerica, la utilizacion de dicha proteina para la preparacion de u

Country Status (26)

Country Link
US (2) US7198781B1 (es)
EP (1) EP0991661B1 (es)
JP (1) JP4402288B2 (es)
KR (1) KR100505172B1 (es)
CN (1) CN1185348C (es)
AR (1) AR013201A1 (es)
AT (1) ATE342915T1 (es)
AU (1) AU758161B2 (es)
BG (1) BG64680B1 (es)
BR (1) BR9812096B1 (es)
CA (1) CA2295936C (es)
CY (1) CY1105895T1 (es)
CZ (1) CZ302488B6 (es)
DE (1) DE69836217T2 (es)
DK (1) DK0991661T3 (es)
EA (1) EA004793B1 (es)
EE (1) EE05519B1 (es)
ES (1) ES2271999T3 (es)
HU (1) HU225855B1 (es)
IL (2) IL122818A0 (es)
NO (1) NO327397B1 (es)
NZ (1) NZ502139A (es)
PL (1) PL199212B1 (es)
PT (1) PT991661E (es)
SK (1) SK287039B6 (es)
WO (1) WO1999002552A2 (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL122818A0 (en) * 1997-07-10 1998-08-16 Yeda Res & Dev Chimeric interleukin-6 soluble receptor/ligand protein analogs thereof and uses thereof
US5919763A (en) * 1998-06-01 1999-07-06 Hadasit Medical Research Services And Development Company Ltd. IL-6/SIL-6R complex for promotion of liver functions
US20040170604A1 (en) 1998-07-06 2004-09-02 Tosoh Corporation IL-6 receptor IL-6 direct fusion protein
EP1443056B2 (en) * 1998-07-06 2012-08-15 Tosoh Corporation IL-6 receptor.IL-6 direct fusion protein
DK1165791T3 (da) * 1999-03-09 2008-02-11 Zymogenetics Inc Humant cytokin som zalpha-receptor-ligand og anvendelse deraf
IL130586A0 (en) * 1999-06-21 2000-06-01 Yeda Res & Dev IL6RIL6 chimera for the treatment of demyelinating diseases
US7446183B2 (en) 2000-06-16 2008-11-04 Asterion Limited Fusion protein comprising growth hormone and growth hormone receptor
IL154777A0 (en) 2000-09-14 2003-10-31 Applied Research Systems Il-6 receptor/il-6 chimera in huntington's disease
DE10106827A1 (de) * 2001-02-14 2002-09-05 Stefan Rose-John Verwendung eines Konjugats aus Interleukin-6(IL-6) und seinem Rezeptor zur Induktion der zellulären Expression des Stammzellfaktors (SCF) und von Flat-3-Ligand (Flt-3L)
DE10107737A1 (de) * 2001-02-16 2002-09-05 S Rose John Christian Albrecht Verwendung eines Konjugats aus IL-6 und einem IL-6 Rezeptor zur Tumortherapie
KR100453877B1 (ko) 2001-07-26 2004-10-20 메덱스젠 주식회사 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
GB0119015D0 (en) * 2001-08-03 2001-09-26 Univ Cardiff A fusion protein
GB2384001B (en) * 2001-12-14 2004-02-04 Asterion Ltd Chimeric growth hormone-growth hormone receptor proteins
IL147412A0 (en) 2001-12-31 2002-08-14 Yeda Res & Dev The use of il6r/il6 chimera in nerve cell regeneration
WO2003092579A2 (en) * 2002-04-29 2003-11-13 Hadasit Medical Research Services And Development Company Ltd. Compositions and methods for treating cancer with an oncolytic viral agent
WO2004069173A2 (en) 2003-01-31 2004-08-19 The Trustees Of The University Of Pennsylvania Methods for modulating an inflammatory response
FR2850621B1 (fr) * 2003-02-04 2006-12-08 Journee Paul Connecteur reliant un bras d'essuie-glace a un balai d'essuyage, qui comporte deux languettes pour le verrouillage transversal de bras d'essuie-glace
DE10321317A1 (de) * 2003-05-13 2004-12-23 Christian-Albrechts-Universität Zu Kiel Verfahren zum Nachweis des funktionellen IL-6/ sIL-6-Rezeptor-Komplexes und Test-Kit zur Durchführung dieses Verfahrens
IL157309A0 (en) * 2003-08-07 2004-02-19 Applied Research Systems Method for the purification of a non-immunoglobulin protein
IL159558A0 (en) 2003-12-24 2004-06-01 Applied Research Systems Use of il-6 in liver injury
IL161672A0 (en) 2004-04-29 2004-09-27 Yeda Res & Dev Compositions and methods for therapy of chemotherapy-induced neuropathy
IL161673A0 (en) 2004-04-29 2004-09-27 Applied Research Systems Compositions and methods for therapy of chemotherapy-induced neuropathy
AU2012261726B2 (en) * 2005-08-29 2015-03-12 Technion Research & Development Foundation Ltd. Media for Culturing Stem Cells
US8476070B2 (en) 2005-08-29 2013-07-02 Technion Research & Development Foundation Limited Media for culturing stem cells
EP1777294A1 (en) 2005-10-20 2007-04-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins
CA2657934C (en) * 2006-07-19 2017-04-04 The Trustees Of The University Of Pennsylvania Wsx-1/p28 as a target for anti-inflammatory responses
ES2704401T3 (es) * 2006-08-02 2019-03-18 Technion Res & Dev Foundation Métodos de expansión de células madre embrionarias en un cultivo en suspensión
WO2008100292A2 (en) 2006-10-16 2008-08-21 Genelux Corporation Modified vaccinia virus strains for use in diagnostic and therapeutic methods
WO2008156655A2 (en) * 2007-06-15 2008-12-24 Genelux Corporation Vaccinia virus vectors encoding a sodium-dependent transporter protein for imaging and/or treatment of tumors
GB0715216D0 (en) * 2007-08-03 2007-09-12 Asterion Ltd Leptin
JP2010535487A (ja) * 2007-08-03 2010-11-25 アステリオン・リミテッド 顆粒球コロニー刺激因子
EA019512B1 (ru) * 2008-07-02 2014-04-30 Эмерджент Продакт Дивелопмент Сиэтл, Ллс Il-6-опосредованная иммунотерапия
KR20110044992A (ko) * 2008-07-02 2011-05-03 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 ＴＧＦ-β 길항제 다중-표적 결합 단백질
EP2387415A1 (en) 2009-01-16 2011-11-23 AGIRx Limited Vaccine compositions
US9018010B2 (en) 2009-11-12 2015-04-28 Technion Research & Development Foundation Limited Culture media, cell cultures and methods of culturing pluripotent stem cells in an undifferentiated state
EP2516467A2 (en) 2009-12-23 2012-10-31 Emergent Product Development Seattle, LLC Compositions comprising tnf-alpha and il-6 antagonists and methods of use thereof
WO2012032521A2 (en) 2010-09-07 2012-03-15 Technion Research & Development Foundation Ltd. Novel methods and culture media for culturing pluripotent stem cells
JP6280031B2 (ja) 2012-03-29 2018-02-14 中外製薬株式会社 抗ｌａｍｐ５抗体およびその利用
KR102539359B1 (ko) 2013-04-19 2023-06-02 싸이튠 파마 감소된 혈관 누출 증후군에 대한 사이토카인 유도체 치료
US20160194369A1 (en) * 2013-08-12 2016-07-07 Merck Sharp & Dohme Corp. Methods and compositions for co-expression of polypeptides of inerest and il6
EP2915569A1 (en) 2014-03-03 2015-09-09 Cytune Pharma IL-15/IL-15Ralpha based conjugates purification method
CN104826093A (zh) * 2015-04-16 2015-08-12 刘永庆 用于治疗慢性传染性肝病的Th2免疫反应拮抗剂及卵黄抗体
CN104922659B (zh) * 2015-07-03 2018-04-20 刘永庆 防治肿瘤和/或慢性结核病的Th2免疫反应抑制剂及其应用
WO2022256688A1 (en) 2021-06-04 2022-12-08 Sonnet BioTherapeutics, Inc. Methods of treating age-related frailty with interleukin-6
CN116064563B (zh) * 2022-11-04 2025-11-11 广州达安基因股份有限公司 白细胞介素-6截短体的制备方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5216128A (en) 1989-06-01 1993-06-01 Yeda Research And Development Co., Ltd. IFN-β2/IL-6 receptor its preparation and pharmaceutical compositions containing it
IL99803A (en) 1991-10-20 1997-02-18 Yeda Res & Dev Pharmaceutical compositions comprising interleukin-6 for the treatment of chronic lymphocytic leukemia and B-cell lymphomas
PL190445B1 (pl) 1995-05-15 2005-12-30 Akademia Medyczna Im K Marcink Genetyczna szczepionka przeciwrakowa
DE19608813C2 (de) 1996-03-07 1998-07-02 Angewandte Gentechnologie Syst Konjugat zur Beeinflussung von Wechselwirkungen zwischen Proteinen
IL122818A0 (en) * 1997-07-10 1998-08-16 Yeda Res & Dev Chimeric interleukin-6 soluble receptor/ligand protein analogs thereof and uses thereof
WO1999032141A1 (en) * 1997-12-19 1999-07-01 Applied Research Systems Ars Holding N.V. Ifnar2/ifn complex

Also Published As

Publication number Publication date
ES2271999T3 (es) 2007-04-16
BR9812096B1 (pt) 2011-09-06
DK0991661T3 (da) 2007-02-05
PL338002A1 (en) 2000-09-25
BR9812096A (pt) 2000-07-18
US7198781B1 (en) 2007-04-03
HU225855B1 (en) 2007-11-28
WO1999002552A2 (en) 1999-01-21
CN1269835A (zh) 2000-10-11
WO1999002552A3 (en) 1999-04-01
EP0991661B1 (en) 2006-10-18
NO20000086D0 (no) 2000-01-07
HUP0002426A3 (en) 2003-01-28
SK287039B6 (sk) 2009-10-07
DE69836217T2 (de) 2007-08-23
JP2001509371A (ja) 2001-07-24
CN1185348C (zh) 2005-01-19
EE05519B1 (et) 2012-02-15
EP0991661A2 (en) 2000-04-12
CZ200075A3 (cs) 2000-08-16
CA2295936A1 (en) 1999-01-21
KR20010021522A (ko) 2001-03-15
US7374912B2 (en) 2008-05-20
AU8127198A (en) 1999-02-08
PL199212B1 (pl) 2008-08-29
NO20000086L (no) 2000-03-08
HK1031895A1 (en) 2001-06-29
AU758161B2 (en) 2003-03-20
JP4402288B2 (ja) 2010-01-20
BG104070A (en) 2000-11-30
IL133972A (en) 2015-07-30
EA200000109A1 (ru) 2000-08-28
HUP0002426A2 (hu) 2000-11-28
CY1105895T1 (el) 2011-02-02
ATE342915T1 (de) 2006-11-15
EA004793B1 (ru) 2004-08-26
EE200000012A (et) 2000-08-15
NZ502139A (en) 2002-03-28
CA2295936C (en) 2009-05-26
US20070172455A1 (en) 2007-07-26
IL122818A0 (en) 1998-08-16
NO327397B1 (no) 2009-06-22
SK62000A3 (en) 2000-07-11
DE69836217D1 (de) 2006-11-30
BG64680B1 (bg) 2005-11-30
CZ302488B6 (cs) 2011-06-15
PT991661E (pt) 2007-01-31
KR100505172B1 (ko) 2005-08-03

Similar Documents

Publication Publication Date Title
EA200000109A1 (ru) Химерный белок растворимого рецептора интерлейкина-6/лиганда, его аналоги и способы применения
ATE271606T1 (de) Die aktivierung von rezeptoren durch gas6
IL143596A0 (en) Vascular endothelial cell growth factor antagonists and uses thereof
ES2185705T3 (es) Proteina bifuncional, preparacion y uso.
ATE295416T1 (de) Humanisiertes grünes-fluoreszenzprotein und methoden
EA200300381A1 (ru) Нуклеиновые кислоты и полипептиды нового рецептора
SE8504872D0 (sv) Selekteringsforfarande och medel herfor
TR199902426T2 (xx) Bitki b�ceklerinin kontrol�.
ES2193145T3 (es) Proteinas procoagulants quimericas.
DK463586A (da) Fsh
ES2058083T3 (es) Anticuerpos monoclonales contra el factor humano de la necrosis tumoral (tnf) y su empleo.
ES2134770T3 (es) Proteinas producidas por los linfocitos humanos, secuencia de adn codante para estas proteinas y aplicaciones farmaceuticas y biologicas.
RU2000111483A (ru) Природные гуманизированные антитела
EA200000298A1 (ru) Агонисты простагландинов и их применение для лечения заболеваний костей
DE69837104D1 (de) An g-protein gekoppelte rezeptoren und deren verwendungen
DK0479948T3 (da) Sammensætninger og fremgangsmåder til syntese af natriuretisk protein-receptor B og anvendelsesfremgangsmåder
ES2129622T3 (es) Receptores para interleuquina-10 de mamifero.
IL143670A0 (en) Methods for the expression of active protein-immunoglobulin fusions, active protein-immunoglobulin fusions obtained thereby and pharmaceutical compositions containing the same
MX24652A (es) Compuestos de adn recombinante, vectores para la expresion de formas zimogenas de proteina c humana, celulas huesped transformadas y metodo para la prduccion recombinante de formas zimogenas de la proteina c humana.
ES2017806A6 (es) Un procedimiento para la obtencion de un anticuerpo monoclonal especifico para un nuevo epitopo del antigeno lfa-l de linfocitos t humanos.
AR030554A1 (es) Moleculas similares a receptores il-17 y usos de las mismas
AR022236A1 (es) Citoquinas mamiferas purificadas; reactivos y metodos relacionados
ES2101716T3 (es) Vectores y compuestos para la expresion de mutantes de glicosilacion de la proteina c humana.
ATE371030T1 (de) Meltrine
BR9713450A (pt) Quimiocinas de mamìfero

Legal Events

Date Code Title Description
FG Grant, registration